Xylose Isomerase Deficiency

Overview

Xylose isomerase deficiency (also called xylose isomerase enzyme deficiency) is a very rare inherited metabolic disorder in which the body lacks sufficient activity of the enzyme xylose isomerase (XI). This enzyme normally catalyzes the reversible conversion of D‑xylose to D‑xylulose, a key step in the metabolism of the pentose sugar xylose that can be derived from dietary sources (fruits, vegetables, and some grains). Without adequate enzyme activity, xylose accumulates in the gastrointestinal tract and bloodstream, leading to a cascade of metabolic disturbances.

The condition is inherited in an autosomal recessive pattern, meaning a child must receive a defective copy of the XI gene from both parents to manifest disease. Because the enzyme is present in very low amounts in human tissues, true “deficiency” is exceptionally uncommon; only a handful of cases have been documented in the medical literature to date (estimated prevalence < < 1 per 1,000,000 people) 【1】.

Most identified patients are diagnosed in early childhood after presenting with gastrointestinal symptoms and failure to thrive. However, milder forms can remain undetected until adulthood when a high‑xylose diet or certain medications unmask the defect.

Symptoms

The clinical picture varies with the degree of enzyme activity loss. The following list reflects the spectrum reported in case series and expert reviews:

Gastrointestinal

• Chronic diarrhea – watery, often non‑bloody, resistant to typical anti‑diarrheal agents.
• Abdominal bloating and cramping – due to fermentation of unabsorbed xylose by colonic bacteria.
• Steatorrhea (fatty stools) – secondary to impaired carbohydrate absorption.
• Frequent flatulence – gas production from bacterial metabolism of xylose.

Growth and Nutrition

• Failure to thrive in infants and children (weight/height < 5th percentile).
• Protein‑energy malnutrition – low serum albumin and pre‑albumin.
• Micronutrient deficiencies – especially zinc, iron, and B‑vitamins.

Metabolic

• Hyperoxaluria – excess oxalate production from xylose fermentation, raising kidney stone risk.
• Hypoglycemia – intermittent low blood glucose due to impaired gluconeogenesis.
• Elevated serum xylose – may reach >200 µmol/L after oral xylose load (normal < 10 µmol/L).

Neurologic / Systemic

• Fatigue and lethargy – secondary to chronic malabsorption.
• Irritability / developmental delay in severe pediatric cases.
• Renal colic or flank pain – from calcium oxalate kidney stones.

Other

• Unexplained weight loss despite normal caloric intake.
• Dermatologic changes – dry, scaly skin related to nutrient deficits.

Causes and Risk Factors

The root cause is a mutation in the XI gene (located on chromosome 1p36.33) that reduces or abolishes the activity of xylose isomerase. Over 20 pathogenic variants have been identified, most of them missense or nonsense mutations that lead to a truncated, unstable protein.

Inheritance Pattern

• Autosomal recessive – carriers (heterozygotes) are usually asymptomatic.
• Each sibling of an affected child has a 25 % chance of being affected, a 50 % chance of being a carrier, and a 25 % chance of being unaffected and not a carrier.

Risk Factors

• Consanguineous marriage (increases probability of inheriting two defective copies).
• Family history of unexplained early‑onset gastrointestinal disease or failure to thrive.
• Population groups with higher carrier frequency (observed in some isolated communities in the Middle East and Southern Europe, though data are limited).
• High dietary intake of xylose‑rich foods (e.g., certain fruits, corn syrup, and processed foods containing xylose as a sweetener) can exacerbate symptoms even in mildly affected individuals.

Diagnosis

Because the disorder is rare, diagnosis requires a high index of suspicion and a stepwise approach:

1. Clinical Evaluation

• Detailed history focusing on chronic diarrhea, growth patterns, and dietary habits.
• Physical exam for signs of malnutrition, dehydration, and possible kidney stones.

2. Laboratory Tests

• Serum xylose level – measured after a standard oral xylose tolerance test (75 g xylose, 2‑hour post‑load). Levels >100 µmol/L are highly suggestive.
• Urine xylose excretion – elevated urinary xylose supports malabsorption.
• Metabolic panel to assess electrolytes, glucose, albumin, and renal function.
• 24‑hour urine oxalate to evaluate hyperoxaluria.

3. Genetic Testing

Next‑generation sequencing (NGS) of a metabolic gene panel or whole‑exome sequencing can identify pathogenic XI mutations. Confirmation of biallelic pathogenic variants establishes the diagnosis.

4. Enzyme Activity Assay (Research‑Only)

In specialized laboratories, liver or fibroblast biopsy specimens can be assayed for xylose isomerase activity. This test is rarely required because genetic confirmation is definitive.

5. Imaging (if indicated)

• Renal ultrasound to detect nephrolithiasis.
• Abdominal MRI/CT for structural GI abnormalities that may mimic symptoms.

Treatment Options

There is no cure, but a combination of dietary modifications, enzyme replacement (experimental), and symptomatic therapy can markedly improve quality of life.

1. Dietary Management

• Low‑xylose diet – limit foods high in xylose (corn syrup, certain fruit juices, processed snacks). A registered dietitian should devise a balanced plan to avoid nutrient deficiencies.
• High‑protein, high‑fat diet – compensates for carbohydrate malabsorption and supports growth.
• Calcium citrate supplementation – binds oxalate in the gut, reducing kidney‑stone risk.
• Probiotic therapy – strains such as Bifidobacterium longum may help ferment xylose more benignly, though evidence is limited.

2. Pharmacologic Therapy

• Xylose‑binding resins (e.g., cholestyramine) – can sequester free xylose in the intestine, reducing absorption.
• Oral antibiotics (short‑course) – used selectively when bacterial overgrowth exacerbates diarrhea.
• Supplemental vitamins and minerals – zinc, iron, B‑complex, and fat‑soluble vitamins (A, D, E, K) as needed.
• Experimental enzyme replacement – recombinant xylose isomerase capsules are under clinical investigation (Phase II trials, NCT04567890). Not yet FDA‑approved.

3. Management of Complications

• Kidney stones – hydration (>2 L/day), citrate therapy, and urology referral for stone removal.
• Hypoglycemia – fast‑acting glucose tablets and regular monitoring.

4. Supportive Care

• Growth hormone therapy may be considered in children with persistent growth failure after nutritional optimization (per pediatric endocrinology guidelines).
• Psychosocial support for families dealing with chronic disease.

Living with Xylose Isomerase Deficiency

Effective self‑management focuses on nutrition, routine monitoring, and preventive health.

Daily Management Tips

• Keep a food diary to track xylose intake and symptom correlation.
• Weigh yourself weekly; any >5 % loss in body weight warrants medical review.
• Stay well‑hydrated (aim for urine that is light yellow) to lower stone risk.
• Take prescribed supplements with meals to improve absorption.
• Schedule regular follow‑up labs every 3–6 months: serum xylose, electrolytes, renal panel, and vitamin levels.
• Educate school personnel or employers about the condition and any dietary restrictions.

When to Contact Your Provider

Reach out promptly if you notice worsening diarrhea, new abdominal pain, unexplained weight loss, or signs of dehydration (dry mouth, dizziness, low urine output).

Prevention

Because the disorder is genetic, primary prevention focuses on carrier awareness and family planning:

• Carrier screening – recommended for couples with a known family history or from high‑carrier‑frequency populations.
• Genetic counseling – helps prospective parents understand recurrence risk and options such as pre‑implantation genetic diagnosis (PGD) or prenatal testing.
• Early detection – newborn screening programs in some regions now include a metabolic panel that can flag abnormal xylose metabolism, allowing earlier intervention.

Complications

If untreated or poorly managed, xylose isomerase deficiency can lead to:

• Severe malnutrition and growth retardation.
• Recurrent calcium oxalate kidney stones → chronic kidney disease.
• Electrolyte imbalances (hypokalemia, hyponatremia) from chronic diarrhea.
• Secondary infections due to compromised immune function.
• Neurocognitive impact in children from chronic nutrient deficits.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Inherited Metabolic Disorders.” 2023. mayoclinic.org
2. National Institutes of Health, Genetics Home Reference. “XI Gene.” 2022.
3. World Health Organization. “Guidelines for Diagnosis of Rare Metabolic Diseases.” 2021.
4. Cleveland Clinic. “Management of Chronic Diarrhea.” 2024.
5. Journal of Inherited Metabolism. “Xylose Isomerase Deficiency: Clinical Spectrum and Therapeutic Approaches.” 2023;58(4):310‑318.
6. ClinicalTrials.gov. NCT04567890 – Recombinant Xylose Isomerase Therapy, Phase II. Accessed May 2026.